Compare NBTB & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBTB | OGN |
|---|---|---|
| Founded | 1856 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.7B |
| IPO Year | N/A | N/A |
| Metric | NBTB | OGN |
|---|---|---|
| Price | $41.88 | $7.12 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | ★ $52.33 | $15.75 |
| AVG Volume (30 Days) | 208.6K | ★ 5.9M |
| Earning Date | 10-27-2025 | 11-10-2025 |
| Dividend Yield | ★ 3.53% | 1.12% |
| EPS Growth | ★ 5.89 | N/A |
| EPS | ★ 3.02 | 1.91 |
| Revenue | $629,728,000.00 | ★ $6,301,000,000.00 |
| Revenue This Year | $27.08 | N/A |
| Revenue Next Year | $9.17 | N/A |
| P/E Ratio | $13.89 | ★ $3.73 |
| Revenue Growth | ★ 16.88 | N/A |
| 52 Week Low | $37.31 | $6.18 |
| 52 Week High | $52.44 | $17.23 |
| Indicator | NBTB | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 55.23 | 40.52 |
| Support Level | $40.80 | $6.95 |
| Resistance Level | $42.58 | $7.86 |
| Average True Range (ATR) | 0.97 | 0.31 |
| MACD | 0.12 | 0.04 |
| Stochastic Oscillator | 71.45 | 18.68 |
NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. Its business, predominantly conducted through NBT Bank, consists of providing commercial banking, retail banking, and wealth management services to customers in its market area, which includes upstate New York, northeastern Pennsylvania, southern New Hampshire, western Massachusetts, Vermont, southern Maine, and central and northwestern Connecticut. The company's reportable segments are Banking and Retirement Plan Administration. A majority of its revenue is generated from the Banking segment.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.